Skip to main content
SOMNOMED LIMITED logo

SOMNOMED LIMITED — Investor Relations & Filings

Ticker · SOM ISIN · AU000000SOM1 LEI · 529900NFR8QFOLJGP577 ASX Manufacturing
Open in API
Filings indexed 982 across all filing types
Latest filing 2024-11-26 Investor Presentation
Country AU Australia
Listing ASX SOM

About SOMNOMED LIMITED

https://somnomed.com

SomnoMed Limited specializes in the development and manufacture of diagnostic and treatment solutions for sleep-related breathing disorders, primarily obstructive sleep apnea (OSA). The company is recognized for its Continuous Open Airway Therapy (COAT), which utilizes custom-fitted oral appliances to maintain an open airway during sleep. Its flagship product line, SomnoDent, offers a range of mandibular advancement devices designed to improve patient compliance and comfort compared to traditional continuous positive airway pressure (CPAP) therapy. SomnoMed focuses on clinical research and technological innovation to provide effective, non-invasive alternatives for patients suffering from mild to moderate OSA and snoring. The company serves a global market, collaborating with sleep dentists and physicians to deliver personalized treatment options that enhance long-term health outcomes and quality of life for individuals with sleep-disordered breathing.

Recent filings

Filing Released Lang Actions
Investor Presentation AGM 11 pages 999.1KB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation Annual General Meeting 27th November 2024' and contains forward-looking statements, company updates, leadership team introductions, financial guidance, and strategic priorities. It is structured as a presentation with slides and summary information rather than a full financial report or regulatory filing. The content focuses on financials, strategy, market position, and company updates typically aimed at investors. There is no indication that this is a full annual report, earnings release, or regulatory filing. The length (6876 characters) and format align with an investor presentation rather than a detailed report or announcement. Therefore, the document best fits the category of Investor Presentation (IP).
2024-11-26 English
AGM Chairman & co-CEO addresses 5 pages 137.4KB
AGM Information Classification · 95% confidence The document is titled '2024 Annual General Meeting' and contains the Chairman's address and co-CEOs' address to shareholders. It discusses the past financial year, management changes, financial performance including revenue and EBITDA figures, operational updates, and future guidance. The content is typical of materials presented at an Annual General Meeting, focusing on company performance, leadership updates, and strategic outlook. There is no indication that this is a full Annual Report (10-K) or an Earnings Release (ER), nor is it a brief announcement or certification. The length and detail suggest it is the AGM presentation or materials shared during the AGM. Therefore, the document fits the category of AGM Information (AGM-R).
2024-11-26 English
AGM results 2 pages 136.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 27th November 2024 reporting the results of the Annual General Meeting (AGM) of SomnoMed Limited held on the same day. It details the voting outcomes for various resolutions, including adoption of the remuneration report, election and re-election of directors, and approval of option issues. The document references compliance with the Corporations Act 2001 and ASX Listing Rules regarding proxy votes and poll results. The content is focused on the official voting results of the AGM rather than the meeting materials or presentations themselves. The document length is relatively short (3067 characters) and it provides detailed voting results, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-11-26 English
Quarterly Activities Report 2 pages 729.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report and Company Update' and provides detailed financial data for the quarter ended 30 September 2024 (Q1 FY25). It includes revenue figures, cash balances, operational comments, and financial review with actual numbers and analysis. The document also discusses company updates such as FDA clearance of a product. The length is 4209 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year and contains actual financial statements and substantive financial data and analysis. Q1 2025
2024-10-22 English
Quarterly Appendix 4C Cash Flow Report 5 pages 759.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities for the quarter ended 30 September 2024. It includes actual financial data such as receipts, payments, cash balances, financing facilities, and reconciliations. The document is over 11,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of detailed financial statements for a quarter aligns with the definition of an Interim / Quarterly Report (IR). The document is not an announcement of a report, nor a certification or regulatory filing. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2025
2024-10-22 English
Notice of Annual General Meeting 24 pages 519.7KB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and details the agenda for the AGM of SomnoMed Limited scheduled for November 27, 2024. It includes items such as receiving the Financial Report, Directors' Report, Auditor's Report for the year ended June 30, 2024, adoption of the Remuneration Report, election and re-election of directors, and approval of share option plans. The document is a formal notice to shareholders about the meeting and the business to be transacted, including voting instructions and proxy appointment details. It does not contain the actual financial statements or reports but rather serves as the official meeting notice. Therefore, it fits the category of AGM Information (AGM-R) rather than the full Annual Report (10-K) or Remuneration Information (DEF 14A). The document length (15,000 characters) is consistent with a detailed AGM notice. Hence, the classification is AGM-R with high confidence.
2024-10-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.